Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 24 June 2005:
Vol. 308. no. 5730, pp. 1878 - 1879
DOI: 10.1126/science.1114854
Prev | Table of Contents | Next

Perspectives

IMMUNOLOGY:
Close to the Edge: Neutralizing the HIV-1 Envelope

Gary J. Nabel

Haynes et al. discuss recent findings in Science and Nature Medicine about antibodies directed to the membrane-proximal region (MPR) of the HIV-1 envelope (ENV) glycoprotein and their possible therapeutic utility. Although these antibodies have the desirable trait of neutralizing the virus in vitro, they occur only rarely in patients, possibly because they also react with self-antigens such as the lipid cardiolipin, and so are eliminated. In addition, the MPR region of HIV-1 may not be accessible to this antibody in patients, limiting its usefulness. Nevertheless, Haynes et al. indicate that further work on neutralizing antibodies that target the conserved Env protein of HIV-1 is warranted.

The author is with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. E-mail: gnabel{at}nih.gov

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design.
M. Montero, N. E. van Houten, X. Wang, and J. K. Scott (2008)
Microbiol. Mol. Biol. Rev. 72, 54-84
   Abstract »    Full Text »    PDF »
Induction of Broad Cross-Subtype-Specific HIV-1 Immune Responses by a Novel Multivalent HIV-1 Peptide Vaccine in Cynomolgus Macaques.
A. Azizi, D. E. Anderson, J. V. Torres, A. Ogrel, M. Ghorbani, C. Soare, P. Sandstrom, J. Fournier, and F. Diaz-Mitoma (2008)
J. Immunol. 180, 2174-2186
   Abstract »    Full Text »    PDF »
Monoclonal Antibodies to Phosphatidylinositol Phosphate Neutralize Human Immunodeficiency Virus Type 1: Role of Phosphate-Binding Subsites.
B. K. Brown, N. Karasavvas, Z. Beck, G. R. Matyas, D. L. Birx, V. R. Polonis, and C. R. Alving (2007)
J. Virol. 81, 2087-2091
   Abstract »    Full Text »    PDF »
Stoichiometry of Murine Leukemia Virus Envelope Protein-Mediated Fusion and Its Neutralization.
W. Ou and J. Silver (2006)
J. Virol. 80, 11982-11990
   Abstract »    Full Text »    PDF »
Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)..
B. Joos, A. Trkola, H. Kuster, L. Aceto, M. Fischer, G. Stiegler, C. Armbruster, B. Vcelar, H. Katinger, and H. F. Gunthard (2006)
Antimicrob. Agents Chemother. 50, 1773-1779
   Abstract »    Full Text »    PDF »
Effect of Epitope Position on Neutralization by Anti-Human Immunodeficiency Virus Monoclonal Antibody 2F5.
W. Ou, N. Lu, S. S. Yu, and J. Silver (2006)
J. Virol. 80, 2539-2547
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)